Eravacycline Dihydrochloride Patent Expiration

Eravacycline Dihydrochloride is Used for treating complicated intra-abdominal infections in adults aged 18 years and older. It was first introduced by Tetraphase Pharmaceuticals Inc in its drug Xerava on Aug 27, 2018.


Eravacycline Dihydrochloride Patents

Given below is the list of patents protecting Eravacycline Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xerava US10961190 Crystalline forms of eravacycline Oct 19, 2037 Tetraphase Pharms
Xerava US11578044 Crystalline forms of eravacycline Oct 19, 2037 Tetraphase Pharms
Xerava US8796245 C7-fluoro substituted tetracycline compounds Aug 07, 2029 Tetraphase Pharms
Xerava US8906887 C7-fluoro substituted tetracycline compounds Dec 28, 2030 Tetraphase Pharms


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳